Clinical trials: HiV1- Positive
HIV-1 Infection
Progesterone Supplementation for HIV-positive Pregnant Women on Anti-Retrovirals
In pregnancy, cART is considered optimal for maternal health and for preventing the emergence of resistance that could compromise further care.
- Trial name
- ProSPAR (NCT02400021)
- Testing
- Prometrium
- Where
- 5 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Mount Sinai Hospital, Canada
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HIV-1-infection
Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV
This is a randomized, double-blinded, placebo-controlled Phase III interventional trial of the nine-valent HPV vaccine (9vHPV) to prevent persistent oral HPV infection in adult men living with HIV.
- Conditions
- HPV Positive Oropharyngeal Squamous Cell Carcinoma, HIV-1-infection, HPV Infection
- Trial name
- NCT04255849
- Testing
- 9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)
- Where
- 3 sites in Brazil, Mexico and 1 more
- Volunteers
- 700 people
- Sponsor
- Weill Medical College of Cornell University
Human Immunodeficiency Virus
Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs
The purpose of this study is to assess the tolerability, adherence and efficacy of single tablet dolutegravir/abacavir/lamivudine antiretroviral therapy in people living with HIV with a history of injection drug use (IDU)…
- Trial name
- TAISTR (NCT02659761)
- Testing
- dolutegravir/abacavir/lamivudine
- Where
- Ireland
- Volunteers
- 33 people
- Sponsor
- University College Dublin
Immune Reconstitution Inflammatory Syndrome
Immune Reconstitution Syndrome in HIV-Infected Patients Taking Antiretroviral Therapy
This study will investigate what factors may lead to the development of immune reconstitution syndrome (IRIS) in HIV-infected patients and what the outcome is after IRIS.
- Trial name
- NCT00286767
- Where
- 3 sites in United States, Thailand
- Volunteers
- 525 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women
The purpose of this study was to evaluate the pharmacokinetics (PK), tolerability, and safety of once-weekly doses of rifapentine (RPT) and isoniazid (INH) in HIV-1-infected and HIV-1-uninfected pregnant and postpartum women with…
- Trial name
- NCT02651259
- Testing
- Rifapentine (RPT), Isoniazid (INH), Pyridoxine (vitamin B6)
- Where
- 5 sites in Haiti, Kenya and 3 more
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals
To ascertain whether the origin of plasma HIV-1-RNA following T cell activation represents the activation of latently infected cells or an increase in cells permissive for replacing viral mutants.
- Trial name
- NCT00001080
- Testing
- Influenza Virus Vaccine, Pneumococcal Vaccine, Polyvalent (23-valent), Lamivudine
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cervical Intraepithelial Neoplasia
Cryotherapy vs. LEEP to Treat Cervical Intraepithelial Neoplasia (CIN) 2/3 Among HIV-positive Women
The purpose of this study is to compare the rate of recurrence of cervical intraepithelial neoplasia among HIV-positive women receiving cryotherapy versus LEEP over 2 years of follow-up and to compare the shedding of HIV-1 from…
- Trial name
- PHE-LEEP (NCT01298596)
- Testing
- Loop Electrosurgical Excision Procedure (LEEP), Cryotherapy
- Where
- Kenya
- Volunteers
- 400 people
- Sponsor
- University of Washington
HIV Infections, HIV Seronegativity
Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults
The purpose of this study is to see if the experimental vaccine, ALVAC-HIV (vCP1452) is safe and to study how the immune system responds to the vaccine.
- Trial name
- NCT00027261
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452)
- Where
- 13 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study of T-20 in HIV-Positive Adults
The purpose of this study is to see if it is safe and effective to give T-20 to HIV-positive adults. T-20 is an anti-HIV drug.
- Trial name
- NCT00002228
- Testing
- Enfuvirtide
- Where
- 11 sites in United States
- Volunteers
- 78 people
- Sponsor
- Trimeris
HIV Infections, Tuberculosis
Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)
Successful therapy of both tuberculosis and HIV disease share similar problems: pill burden, drug interaction, adherence challenge and toxicity.
- Trial name
- NCT00115609
- Testing
- efavirenz, tenofovir DF, emtricitabine
- Where
- France
- Volunteers
- 70 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections
Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients
The purpose of this study is to identify an optimal dose combination(s) of tipranavir (TPV) and ritonavir (RTV) for antiretroviral treatment naïve HIV-1 infected patients that can be used in pivotal trial by assessing the…
- Trial name
- NCT00530920
- Testing
- tipranavir, ritonavir
- Where
- 12 sites in Germany, Italy and 1 more
- Volunteers
- 85 people
- Sponsor
- Boehringer Ingelheim
HIV Infections, Tuberculosis
Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis
Raltegravir is a potent antiretroviral agent that could be used as an alternative to efavirenz in HIV-1 infected patients with tuberculosis.
- Trial name
- NCT00822315
- Testing
- efavirenz, raltegravir
- Where
- 9 sites in Brazil, France
- Volunteers
- 155 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections, Lipodystrophy
A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients
The purpose of this study is to see if the findings of increased lactic acid and abnormal fat distribution get better when d4T is replaced with abacavir, abacavir plus lamivudine, or Combivir (a pill containing lamivudine plus…
- Trial name
- NCT00005764
- Testing
- Lamivudine/Zidovudine, Abacavir sulfate, Lamivudine
- Where
- 31 sites in United States
- Volunteers
- 100 people
- Sponsor
- Glaxo Wellcome
HIV Infections
Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
The purpose of this study is to see if giving HIV-positive patients an HIV vaccine plus anti-HIV drugs can help lower HIV levels in the blood (viral load).
- Trial name
- NCT00005001
- Testing
- HIV-1 Immunogen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Agouron Pharmaceuticals
HIV-1 Infection
A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (behavior in the body) of bevirimat administered for 15 days to HIV-positive individuals.
- Trial name
- NCT01097070
- Testing
- Bevirimat
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Myrexis Inc.
HIV Infection, HIV-1 Infection
A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc
Healthy volunteers are being recruited for this pharmacokinetics study. The objective is to characterize the pharmacokinetic properties of maraviroc alone and when administered with rifabutin and to assess rifabutin and…
- Conditions
- HIV Infection, HIV-1 Infection, Mycobacterium Avium Complex (MAC)
- Trial name
- RIFAMARA (NCT01894776)
- Testing
- Rifabutin, Maraviroc
- Where
- Canada
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Ottawa Hospital Research Institute
HIV Infections
A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors
Indinavir is usually taken three times a day. The purpose of this study is to see if it is safe and effective to take indinavir only twice a day plus nelfinavir (also taken twice a day) and efavirenz (taken once a day).
- Trial name
- NCT00002235
- Testing
- Indinavir sulfate, Nelfinavir mesylate, Efavirenz
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3
The purpose of this study is to examine how rIL-2 affects HIV-positive patients with CD4 counts over 300 cells/mm3 who are on anti-HIV drug therapy.
- Trial name
- NCT00000949
- Testing
- Aldesleukin
- Where
- 15 sites in United States
- Volunteers
- 460 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Tuberculosis
Appropriate Timing of HAART in Co-infected HIV/TB Patients
To study the optimal timing to initiate antiretroviral therapy in HIV-infected patients who are receiving tuberculosis treatment between at 4 weeks and at 12 weeks after tuberculosis treatment by comparing the composite end point…
- Trial name
- TIME (NCT01014481)
- Testing
- tenofovir, lamivudine, efavirenz
- Where
- Thailand
- Volunteers
- 156 people
- Sponsor
- Bamrasnaradura Infectious Diseases Institute
HIV Infections, Tuberculosis
Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy
A 48 week, randomized, open-label, two arm study to compare the efficacy, safety and tolerability of HAART containing nevirapine 400 mg/day versus nevirapine 600 mg/day in HIV-1 infected patients started at 2-6 weeks after…
- Trial name
- NCT00476853
- Testing
- HAART containing nevirapine
- Where
- 6 sites in Thailand
- Volunteers
- 42 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration